BRCA2 and metastatic prostate carcinoma: To target this germline BRCA2 mutation, olaparib, a PARP inhibitor that has demonstrated efficacy against metastatic prostate cancer,19 was initially administered and led to a complete clinical response after 3 months of treatment.